Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.
"Our first IND submission is a significant milestone for Senesco," stated Leslie J. Browne, Ph.D, President and Chief Executive Officer of Senesco Technologies Inc. "SNS01-T could be a new way of reprogramming cancer cells to respond to natural death signals. It is designed to regulate what we believe is an important growth control switch that induces programmed cell death, also known as apoptosis. Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard treatment regimens. If this therapeutic approach is successful, we believe it has the potential to change the progression of the disease and significantly impact patients' lives."
Multiple myeloma is a cancer of plasma cells, a type of white blood cell normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Up to two-thirds of patients with the disease currently survive less than five years. Senesco was previously granted orphan drug status for SNS01-T, the Company's lead drug candidate for treatment of multiple myeloma.
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts